T. Rowe Price Associates’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q1 | – | Sell |
-650,842
| Closed | -$11.2M | – | 2590 |
|
|
2015
Q4 | $11.2M | Buy |
650,842
+1,670
| +0.3% | +$28.7K | ﹤0.01% | 1259 |
|
|
2015
Q3 | $13.7M | Sell |
649,172
-9,198
| -1% | -$194K | ﹤0.01% | 1223 |
|
|
2015
Q2 | $32.6M | Sell |
658,370
-2,910
| -0.4% | -$144K | 0.01% | 983 |
|
|
2015
Q1 | $51.8M | Sell |
661,280
-5,240
| -0.8% | -$410K | 0.01% | 833 |
|
|
2014
Q4 | $40.4M | Sell |
666,520
-148,000
| -18% | -$8.97M | 0.01% | 907 |
|
|
2014
Q3 | $34.7M | Buy |
814,520
+335,880
| +70% | +$14.3M | 0.01% | 950 |
|
|
2014
Q2 | $29.6M | Buy |
478,640
+215,189
| +82% | +$13.3M | 0.01% | 1015 |
|
|
2014
Q1 | $17.1M | Buy |
263,451
+258,991
| +5,807% | +$16.8M | ﹤0.01% | 1154 |
|
|
2013
Q4 | $251K | Buy |
4,460
+2,980
| +201% | +$168K | ﹤0.01% | 2227 |
|
|
2013
Q3 | $91K | Sell |
1,480
-85,090
| -98% | -$5.23M | ﹤0.01% | 2394 |
|
|
2013
Q2 | $5.06M | Buy |
+86,570
| New | +$5.06M | ﹤0.01% | 1403 |
|